5 Jul 2021 12:29
Ap19
Β
Β
Β
FORMΒ 8.3
Β
IRISHΒ TAKEOVERΒ PANEL
Β
DISCLOSUREΒ UNDERΒ RULEΒ 8.3Β OFΒ THEΒ IRISHΒ TAKEOVERΒ PANEL ACT,Β 1997,Β TAKEOVERΒ RULES,Β 2013
Β
DEALINGSΒ BYΒ PERSONSΒ WITHΒ INTERESTSΒ INΒ RELEVANTΒ SECURITIESΒ REPRESENTINGΒ 1%Β ORΒ MORE
Β
1. KEYΒ INFORMATION
Β
Name of person dealing (Note 1) | J.P. Morgan Securities LLC |
Company dealt in | Xeris Pharmaceuticals, Inc. |
Class of relevant security to which the dealings being disclosed relate (Note 2) | $0.001 common stock |
Date of dealing | 02 July 2021 |
Β
2. INTERESTSΒ ANDΒ SHORTΒ POSITIONS
Β
(a) InterestsΒ andΒ shortΒ positionsΒ (followingΒ dealing)Β inΒ theΒ classΒ ofΒ relevantΒ securityΒ dealtΒ inΒ (NoteΒ 3)
Β | Long | Short | ||||
Β | Number | Β | (%) | Number | Β | (%) |
(1) Relevant securities | 2,063,366 3.11 | 417,692 0.63 | ||||
(2) Derivatives (other than options) | 123,876 0.19 | 5,662 0.01 | ||||
(3) Options and agreements to purchase/sell | 0.00 | 0.00 | ||||
Total | 2,187,242 3.30 | 423,354 0.64 | ||||
| Β | Β | Β | Β | Β | Β | Β |
Β
Β
Β
Β
1. DEALINGSΒ (NoteΒ 4)
Β
(a) PurchasesΒ andΒ sales
Β
Β Purchase/sale | Β Number of relevant securities | Β Price per unit (USD) Β (Note 5) |
Purchase (New Borrow) Β Purchase (Loan Return) Β Purchase Purchase Purchase Purchase Purchase Purchase Purchase Β Sale | 151,900 Β 13,300 Β 231 1,405 4,678 9,359 400 2,545 100 Β 9,359 | N/A Β N/A Β 4.2500 USD 4.2348 USD 4.2003 USD 4.1791 USD 4.1450 USD 4.1033 USD 4.1000 USD Β 4.1791 USD |
Β
Β
Β
(b) DerivativesΒ transactionsΒ (otherΒ thanΒ optionsΒ transactions)
Β
Product name, e.g. CFD | Nature of transaction (Note 6) | Number of relevant securities (Note 7) | Price per unit (USD) (Note 5) |
Equity Swap | Decrease Long | 9,359 | 4.1791 USD |
Β
Β
Β
(c) OptionsΒ transactionsΒ inΒ respectΒ ofΒ existingΒ relevantΒ securities
Β
Β
(i) Writing,Β selling,Β purchasingΒ orΒ varying
Β
Β
Product name, e.g. call option | Writing, selling, purchasing, varying etc. | Number of securities to which the option relates (Note 7) | Exercise price | Type, e.g. American, European etc. | Expiry date | Option money paid/received per unit (Note 5) |
Β | Β | Β | Β | Β | Β | Β |
Β
Β
(ii) Exercising
Β
Product name, e.g. call option | Number of securities | Exercise price per unit (Note 5) |
Β | Β | Β |
Β
Β
(d) OtherΒ dealingsΒ (includingΒ transactionsΒ inΒ respectΒ ofΒ newΒ securities)Β (NoteΒ 4)
Β
Nature of transaction (Note 8) | Details | Price per unit (if applicable) (Note 5) |
Β | Β | Β |
Β
Β
Ap21
Β
2. OTHERΒ INFORMATION
Β
Agreements,Β arrangementsΒ orΒ understandingsΒ relatingΒ toΒ optionsΒ orΒ derivatives
Β
Β
Β
Β
FullΒ detailsΒ ofΒ anyΒ agreement,Β arrangementΒ orΒ understandingΒ betweenΒ theΒ personΒ disclosing andΒ anyΒ otherΒ personΒ relatingΒ toΒ theΒ
votingΒ rightsΒ ofΒ anyΒ relevantΒ securitiesΒ underΒ anyΒ option referredΒ toΒ onΒ thisΒ formΒ orΒ relatingΒ toΒ theΒ votingΒ rightsΒ orΒ futureΒ acquisitionΒ
orΒ disposalΒ ofΒ anyΒ relevantΒ securitiesΒ toΒ whichΒ anyΒ derivativeΒ referredΒ toΒ onΒ thisΒ formΒ isΒ referenced.Β IfΒ none,Β this shouldΒ beΒ stated.
Β
None
Β
Β
Β
Β
Β
Β
Β
Β
IsΒ aΒ SupplementalΒ FormΒ 8Β attached?Β (NoteΒ 9) Β NO
Β
Date of disclosure | Β 05 July 2021 |
Contact name | Alwyn Basch |
Telephone number | 0207 742 7407 |
If a connected EFM, name of offeree/offeror with which connected | N/A |
If a connected EFM, state nature of connection (Note 10) | N/A |
Β
Follow the stocks